ARL13A

Across TCGA pan-cancer cohorts, ARL13A Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ARL13A data layer compared with 23 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ARL13A Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated ARL13A expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

UCEC, SARC, and SKCM are the cancer types where ARL13A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.956	0.626	.026	10	view →
SARC	OS	Median	All	0.210	0.745	.014	6	view →
SKCM	DFS	Median	III,IV	0.015	0.648	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

ARL13A–UCEC (DFS)

Open the UCEC breakdown →